Trial result ·
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This study looked at blood markers in endometrial cancer. The NRG-GY012 trial tested olaparib, cediranib and both together. It had 120 people whose cancer had returned, persisted or spread. Blood was taken at the start, at cycle 4 day 1 and at progression. The team asked if protein markers in the blood predict outcomes.
What they found
A 2.9 pg/mL IL-6 cut point from an earlier trial failed here. IL-6 was linked to overall survival when split at the median, 4.2 pg/mL. People above 4.2 pg/mL had a worse outlook. Higher IL-6 was tied to more survival benefit from cediranib, but this was not significant. OPN and PlGF may also predict benefit. Higher PlGF went with more benefit from cediranib.
What it means for patients
The team says IL-6 may predict outcome. They say OPN and PlGF are new possible markers in people on anti-angiogenic therapy. They say more testing is warranted.
Why it is not certain yet
The 2.9 pg/mL cut point from an earlier trial did not validate. Some of the links came from secondary analyses. Not all of the 120 people gave baseline samples. The abstract calls the markers potential, not proven.
Source
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.
PubMed · PMID 42870635We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Endometrial cancer publications